Holen Sie sich die Stockscreener-App
8.76
8.42%
0.68
Handel nachbörslich:
9.01
0.25
+2.85%
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Passage Bio advances frontotemporal dementia trial and reports 2025 results - MSN
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena - AD HOC NEWS
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bond Watch: Can Passage Bio Inc reach all time highs this year2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Oppenheimer Initiates Coverage on PASG with Outperform Rating | - GuruFocus
Oppenheimer Initiates Passage Bio at Outperform - Moomoo
Baird initiates Passage Bio stock coverage with outperform rating By Investing.com - Investing.com India
Baird initiates Passage Bio stock coverage with outperform rating - investing.com
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Oppenheimer initiates Passage Bio stock with outperform rating - Investing.com UK
Oppenheimer initiates Passage Bio stock with outperform rating By Investing.com - za.investing.com
Passage Bio, Inc. (NASDAQ:PASG) Receives $28.00 Average Price Target from Brokerages - Defense World
Stock List: Research Stocks from Around the World - gurufocus.com
Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo - AD HOC NEWS
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Options Flow: Can Sprout Social Inc sustain earnings growth2026 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
Passage Bio's 2025 net loss narrows - TradingView
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio management to present at two healthcare conferences - MSN
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):